-
Eloxx Pharmaceuticals Will Launch ELX-02 Trial in US for Cystic Fibrosis
Eloxx Pharmaceuticals will launch a Phase 2 clinical study in the U.S. to test ELX-02 in people with cystic fibrosis who carry the G542X mutation. Read more about it.
What are your thoughts about this study and its findings?
Sorry, there were no replies found.
Log in to reply.